


Videoconference

Results of the 2020-2021 financial year
ended on March 31, 2021



- In partnership with Teva Pharmaceuticals
- Internal programs
- In partnership with AIC
- With the support of the Bill and Melinda Gates Foundation
- With the support of Unitaïd
- *NDA :New Drug Application
- Animal Health product (different clinical development process)

Financial resources

- 51 M€ cash and investments
 - 47,1 M€ in cash
 - 3,9 M€ in non-risky financial assets

Financial resources

- *Income from ordinary activities:*
11,8 M€ (+96%)
 - Revenue: 8,2 M€ (+187%)
 - Research Tax Credit: 3,6 M€ (+14%)

Financing

- *EIB: 5 M€ (3rd tranche)*
- *State Guaranteed Loans (PGE): 13,7 M€*
- *Capital increases: 42 M€ (net)*

Expenses

- *Expenses: 27,1 M€ (+8%)*
 - *R&D: 19,6 M€*
 - *Marketing & BD: 1,8 M€*
 - *General & administrative: 5,8 M€*

Financial debt

- *Gross financial debt: 42,3 M€*
- *Net financial debt: (8,8) M€*



Tank you

MedinCell
3, rue des frères Lumière
34830 Jacou • France

www.medincell.com